Brought to you by 
Novartis to co-promote Retisert in the US with Bausch & Lomb
07 Mar 2006
Executive Summary
Novartis Ophthalmics will co-promote Bausch & Lomb's Retisert (fluocinolone intravitreal implant) 0.59mg to US retinal specialists that have patients with chronic noninfectious posterior segment uveitis.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com